semaglutide and lipedema Are you living with Lipedema? @lipedema_fndn is conducting a survey needs your voice! Whether you've taken GLP-1 receptor agonist / GLP-1 / GIP dual agonist medications (e.g., Ozempic®, Wegovy®, Saxenda®, Zepbound® Missed our live with @DrRichardJBrown?

Reduction in appetite Zepbound mimics two natural hormones GIP and GLP-1 that regulate blood sugar and hunger

GLP-1 Receptor Agonist Market Report Snapshot Market Segmentation By Molecule (Liraglutide, Dulaglutide, Semaglutide, Tirzepatide, and Others): The tirzepatide segment earned USD 27.14 billion in 2025, primarily due to superior efficacy in both glycemic control and weight reduction, rapid uptake among healthcare providers, and expanded diabetes and obesity indications, positioning it as a preferred GLP-1 therapy option

Personal Interview

SOUTH PARK: THE END OF OBESITY is a South Park special about weight-loss drugs, the United States health care system, and body image

In January 2020, spending on Ozempic, a Type 2 diabetes-indicated GLP-1, was just $4.6 million, while Wegovyone of the most prominent FDA-approved GLP-1s for weight managementhad not yet been introduced